9,491 reports of this reaction
7.1% of all LEUPROLIDE ACETATE reports
#1 most reported adverse reaction
HOT FLUSH is the #1 most commonly reported adverse reaction for LEUPROLIDE ACETATE, manufactured by TOLMAR Inc.. There are 9,491 FDA adverse event reports linking LEUPROLIDE ACETATE to HOT FLUSH. This represents approximately 7.1% of all 133,873 adverse event reports for this drug.
Patients taking LEUPROLIDE ACETATE who experience hot flush should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOT FLUSH is moderately reported among LEUPROLIDE ACETATE users, representing a notable but not dominant share of adverse events.
In addition to hot flush, the following adverse reactions have been reported for LEUPROLIDE ACETATE:
The following drugs have also been linked to hot flush in FDA adverse event reports:
HOT FLUSH has been reported as an adverse event in 9,491 FDA reports for LEUPROLIDE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOT FLUSH accounts for approximately 7.1% of all adverse event reports for LEUPROLIDE ACETATE, making it one of the most commonly reported side effect.
If you experience hot flush while taking LEUPROLIDE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.